Sotuletinib

Overview

Sotuletinib (BLZ945) is a potent, selective, orally active and brain-penetrant CSF-1R ( c-Fms ) inhibitor with an IC 50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib can be used for microglia depletion, and for tumor and CNS-related disease research .

Application

Products | Products > Disease Areas > Blood Disease | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Neurological Disease | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > c-Fms

Product Information

• Catalog No.: HY-12768
• CAS No.: 953769-46-5
• Molecular Formula: C20H22N4O3S
• Molecular Weight: 398.48
• Purity: 99.97%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.08 mg/mL (5.22 mM); Clear solution
• Availability: In-stock

Source

Original product source